Open Payments

ST BERNARDS MEDICAL CENTER

Type
Teaching hospital
Where
Jonesboro, AR
Medicare CCN
040020
Received
$484,058 in 55 records, 2020 ($333 general, $483,724 research)
Source
CMS Open Payments search ↗

By year

Program yearKindRecordsAmount
2020General payment4$333
2020Research payment51$483,724

By company

CompanyRecordsAmountYears
Novartis Pharmaceuticals Corporation2$286,8882020
Boston Scientific Corporation14$59,3622020
Eli Lilly and Company4$40,9532020
E.R. Squibb & Sons, L.L.C.1$23,0622020
Baxter Healthcare2$20,5072020
Amgen Inc.9$15,5622020
Incyte Corporation3$12,5782020
PFIZER INC.1$8,5002020
Celgene Corporation1$5,7352020
CSL Behring2$4,1952020
SEAGEN INC.1$4,0002020
Pharmacyclics LLC, an AbbVie Company9$1,3502020
Merck Sharp & Dohme LLC2$1,0272020
LEICA MICROSYSTEMS INC.3$2962020
GE HEALTHCARE1$372020

By nature of payment

NatureRecordsAmount
Research payment51$483,724
Gift3$296
Grant1$37

Records

DateCompanyAmountNatureFormProductStudyYear
2020-12-21Boston Scientific Corporation$6,134Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-11-16Boston Scientific Corporation$7,686Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-11-11Boston Scientific Corporation$309Research paymentIn-kind items and servicesCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-11-11Boston Scientific Corporation$2Research paymentIn-kind items and servicesCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-10-19Boston Scientific Corporation$9,323Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-10-09Amgen Inc.$1,078Research paymentIn-kind items and servicesNplate Biological, HematologyLCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 12020
2020-09-30Incyte Corporation$4,446Research paymentCash or cash equivalentEvaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S2020
2020-09-30Incyte Corporation$3,578Research paymentCash or cash equivalentEvaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S2020
2020-09-29Baxter Healthcare$9,301Research paymentCash or cash equivalentRenal - Amia Device, RenalPerformance evaluation of the AMIA Automated Peritoneal Dialysis -APD- Solution Generation System in patients using the 2020
2020-09-25SEAGEN INC.$4,000Research paymentCash or cash equivalentTUKYSA Drug, OncologyStudy of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metas2020
2020-09-14Novartis Pharmaceuticals Corporation$284,120Research paymentCash or cash equivalentKISQALI Drug, ONCOLOGYRIBOCICLIB STANDARD ENDOCRINE THERAPY IN PATIENTS WITH HR HER2 EARLY BC AT HIGH AMP INTERMEDIATE RISK FOR RECURRENCE2020
2020-08-29PFIZER INC.$8,500Research paymentCash or cash equivalentA PHASE 3 RANDOMIZED DOUBLEBLINDED PLACEBOCONTROLLED TRIAL TO EVALUATE THE EFFICACY AND SAFETY OF A RESPIRATORY SYNCYTIA2020
2020-08-21Amgen Inc.$925Research paymentIn-kind items and servicesNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-08-04Boston Scientific Corporation$2,449Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-07-28Merck Sharp & Dohme LLC$787Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab2020
2020-07-06Boston Scientific Corporation$9,702Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-07-06Boston Scientific Corporation$1,144Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-06-23CSL Behring$3,000Research paymentCash or cash equivalentA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-06-23Amgen Inc.$2,500Research paymentCash or cash equivalentNplate Biological, HematologyLCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 22020
2020-06-15Merck Sharp & Dohme LLC$240Research paymentIn-kind items and servicesMK-7339 Drug, ONCOLOGYA Phase 3 Study of Pembrolizumab MK-3475 in Combination with Concurrent Chemoradiation Therapy Followed by Pembrolizumab2020
2020-06-11Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-06-08Boston Scientific Corporation$6,516Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-06-02Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-06-02Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-06-02Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-06-02Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-05-20Boston Scientific Corporation$370Research paymentIn-kind items and servicesCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-04-20Boston Scientific Corporation$4,452Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-04-17Amgen Inc.$2,593Research paymentIn-kind items and servicesNplate Biological, HematologyLCM: A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 22020
2020-04-08Amgen Inc.$71Research paymentIn-kind items and servicesNplate Biological, HematologyLCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 12020
2020-03-27Amgen Inc.$925Research paymentIn-kind items and servicesNplate Biological, HematologyLCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 12020
2020-03-26CSL Behring$1,195Research paymentIn-kind items and servicesA Phase 3, Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Investigate the Efficacy a2020
2020-03-16Boston Scientific Corporation$4,882Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-03-16LEICA MICROSYSTEMS INC.$195GiftCash or cash equivalentN/A Device, CANCER DIAGNOSTICS2020
2020-03-16LEICA MICROSYSTEMS INC.$77GiftCash or cash equivalentN/A Device, CANCER DIAGNOSTICS2020
2020-03-16LEICA MICROSYSTEMS INC.$22GiftCash or cash equivalentN/A Device, CANCER DIAGNOSTICS2020
2020-03-10Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-03-10Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-03-10Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-03-10Pharmacyclics LLC, an AbbVie Company$150Research paymentCash or cash equivalentImbruvica Drug, OncologyPCYC-1134M-CA2020
2020-02-18Boston Scientific Corporation$2,341Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-02-17Celgene Corporation$5,735Research paymentCash or cash equivalentRevlimid Drug, HematologyCelgene - Connect MDS/AML2020
2020-02-13Novartis Pharmaceuticals Corporation$2,768Research paymentCash or cash equivalentVOTRIENT Drug, ONCOLOGYA RANDOMIZED DOUBLE BLIND PLACEBO CONTROLLED PHASE III STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PAZOPANIB AS ADJUVAN2020
2020-02-10Amgen Inc.$17Research paymentIn-kind items and servicesNplate Biological, HematologyLCM:A Phase 3 Randomized Placebo Controlled Study of the Treatment of CIT for Solid Tumors- Study 12020
2020-02-05E.R. Squibb & Sons, L.L.C.$23,062Research paymentCash or cash equivalentOPDIVO Biological, OncologyLung cancer molecular profiling and clinical outcomes in US oncology community practices2020
2020-01-30Amgen Inc.$7,446Research paymentCash or cash equivalentNeulasta Biological, OncologyProspective Observational Study of Onpro vs SOC.2020
2020-01-28Eli Lilly and Company$1,154Research paymentIn-kind items and servicesA STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN2020
2020-01-28Eli Lilly and Company$387Research paymentIn-kind items and servicesA RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD2020
2020-01-22Incyte Corporation$4,554Research paymentCash or cash equivalentEvaluation Of Ruxolitinib And Azacytidine Combination As A Therapy For Patients With Myelofibrosis And Myelodysplastic S2020
2020-01-21Eli Lilly and Company$22,853Research paymentCash or cash equivalentA RANDOMIZED, OPEN-LABEL, PHASE 3 STUDY OF ABEMACICLIB COMBINED WITH STANDARD ADJUVANT ENDOCRINE THERAPY VERSUS STANDARD2020
2020-01-21Boston Scientific Corporation$4,047Research paymentCash or cash equivalentCLINICAL TRIAL PRODUCT Device, CLINICAL TRIAL PRODUCTDES BTK2020
2020-01-17Eli Lilly and Company$16,559Research paymentCash or cash equivalentA STUDY OF ABIRATERONE ACETATE PLUS PREDNISONE WITH OR WITHOUT ABEMACICLIB (LY2835219) IN PARTICIPANTS WITH PROSTATE CAN2020
2020-01-13Baxter Healthcare$11,205Research paymentCash or cash equivalentRenal - Amia Device, RenalPerformance evaluation of the AMIA Automated Peritoneal Dialysis -APD- Solution Generation System in patients using the 2020
2020-01-09Amgen Inc.$4Research paymentIn-kind items and servicesGALACTIC - HF2020
2020-01-08GE HEALTHCARE$37GrantIn-kind items and services2020

CMS Open Payments: payments and transfers of value that drug and medical device makers and group purchasing organizations report to Medicare, program years 2019 on, as published by CMS (general, research and ownership records; refreshed by CMS each June and January). Links to other records on this site are by name (and state) only.

The area Census

Craighead CountyJonesboro city

County outline, the place (blue), the tract (orange) and the ZIP center (dot).

In Jonesboro, AR, county Craighead County, AR, state Arkansas; placed by its city name.

MeasurePlace (city or town)
Jonesboro, AR
County
Craighead County, AR
State
Arkansas
Population B0100380,137113,2493,049,391
Population, 2020 census P178,576111,2313,011,524
Median age B0100233.934.538.5
Under 18 B0100124.0%25.2%23.1%
65 and over B0100114.2%13.9%17.6%
Households B1100131,91344,4371,205,987
Foreign born B050024.6%3.7%5.4%
Median household income B19013$55,424$59,548$60,773
Median family income B19113$72,057$75,703$76,968
Per capita income B19301$33,544$33,774$34,225
Poverty rate B1700122.8%20.1%16.0%
Unemployment rate B230256.3%5.6%4.9%
Civilian labor force B2302538,91255,5351,411,269
Mean commute (minutes) B0801318.019.622.5
Bachelor's degree or higher B1500331.8%29.7%25.7%
Housing units B2500135,00248,8851,394,673
Owner-occupied B2500354.3%60.1%66.4%
Renters B2500345.7%39.9%33.6%
Median home value B25077$223,200$210,400$188,000
Median gross rent B25064$956$958$947
White, not Hispanic B0300263.0%70.8%67.4%
Black B0300222.7%16.6%14.6%
Hispanic or Latino B030027.5%6.3%9.0%
Asian B030021.6%1.2%1.6%
American Indian and Alaska Native B030020.2%0.2%0.3%

Economy now FRED unemployment 3.9% in Sep 2026 (4.2% a year earlier); per capita personal income $61,697 in 2025, up 31% in five years (+5.2% after inflation); Unemployment rate: 3.9% in Sep 2016 to 3.8% in Oct 2026; low 2.9%, high 10.1% the state; Source: FRED, Federal Reserve Bank of St. Louis.

Data: IPUMS NHGIS (ACS 2020-2024 and the 2020 census); each figure links to its table for that area at data.census.gov. Records are placed by ZIP code and city name, not street address. More: everything FURP has in Jonesboro, AR.

Comments

Anonymous: no account or email. Up to 2,000 characters, at most one link. Comments are checked automatically; some wait for review.